News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
257,400 Results
Type
Article (13403)
Company Profile (73)
Press Release (243924)
Section
Business (87613)
Career Advice (455)
Deals (15310)
Drug Delivery (59)
Drug Development (36416)
Employer Resources (49)
FDA (6205)
Job Trends (6172)
News (149426)
Policy (13976)
Tag
Academia (436)
Africa (311)
Allergies (11)
Alliances (22995)
ALS (10)
Alzheimer's disease (312)
Antibody-drug conjugate (ADC) (18)
Approvals (6190)
Arizona (29)
Artificial intelligence (35)
Asia (19532)
Australia (2518)
Bankruptcy (143)
Best Places to Work (4151)
Biosimilars (24)
C2C Services and Suppliers (10601)
California (294)
Canada (297)
Cancer (56)
Cardiovascular disease (11)
Career advice (398)
Cell therapy (17)
China (21)
Clinical research (29851)
Collaboration (24)
COVID-19 (729)
Cystic fibrosis (20)
Delaware (11)
Diabetes (10)
Diagnostics (1181)
Diversity, equity & inclusion (13)
Drug pricing (38)
Earnings (30826)
Employer resources (43)
Europe (38196)
Events (36045)
Executive appointments (14)
FDA (6221)
Florida (23)
Funding (13)
Gene editing (12)
Gene therapy (28)
GLP-1 (242)
Government (1238)
Healthcare (3480)
Hotbed/Location (177948)
Illinois (50)
Indiana (42)
Infectious disease (731)
Inflammatory bowel disease (39)
Interviews (57)
IPO (5755)
IRA (14)
Job creations (2046)
Job search strategy (371)
Kansas (45)
Layoffs (159)
Legal (3394)
Liver cancer (16)
Lung cancer (13)
Management (16)
Manufacturing (27)
Maryland (47)
Massachusetts (198)
Medical device (1247)
Medtech (1248)
Mergers & acquisitions (9433)
Metabolic disorders (65)
Neuroscience (345)
New Jersey (33)
New York (27)
NextGen Class of 2024 (1569)
Non-profit (586)
North Carolina (68)
Obesity (42)
Opinion (102)
Patents (21)
Pennsylvania (14)
People (28079)
Phase I (7777)
Phase II (12626)
Phase III (11335)
Podcasts (32)
Policy (23)
Postmarket research (1397)
Preclinical (3116)
Rare diseases (29)
Real estate (2623)
Recruiting (17)
Regulatory (9628)
Reports (12)
Research institute (562)
Resumes & cover letters (55)
South America (496)
Startups (1622)
Texas (27)
United States (969)
Vaccines (77)
Washington State (30)
Weight loss (38)
Date
Today (24)
Last 7 days (181)
Last 30 days (726)
Last 365 days (13694)
2024 (7742)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
257,400 Results for "bioray pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Clinical Trial Application (IND) for BioRay Pharmaceutical’s BR105 Injection Receives U.S. FDA Approval
BioRay Pharmaceutical Co., Ltd. announced on October 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration.
October 24, 2023
·
2 min read
Drug Development
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.
November 7, 2023
·
2 min read
Policy
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
Recently, BioRay Pharmaceutical Co., Ltd. announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection, indicated for the treatment of CD20-positive diffuse large B-cell lymphoma, was officially approved for marketing by the National Medical Products Administration.
September 13, 2023
·
2 min read
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
BioRay Pharmaceutical Co., Ltd. announced that the Investigational New Drug application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration .
May 24, 2023
·
2 min read
Biotech Beach
Bioray Inc. Releases New Products for Teens at Expo West 2023 in Anaheim
Bioray Inc., The Natural Detox Company, is launching RAYZ ® for teens at Natural Products Expo West 2023 at the Anaheim Convention Center March 9th through March 11th , 2023.
March 3, 2023
·
1 min read
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Nascent Biotech, Inc. is pleased to announce that the Company has received a payment totaling USD $750,000 from BioRay Pharmaceutical, Ltd.
February 23, 2022
·
3 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
Business
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent’s Pritumumab
Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech has entered into a license agreement with BioRay Pharmaceutical Co Ltd
May 19, 2021
·
4 min read
BioMidwest
Nascent Biotech Regains Worldwide Rights for Pritumumab
Nascent Biotech, Inc. announced that the Company and China based BioRay Pharmaceutical Co have mutually agreed to terminate the license agreement entered into on March 31, 2021.
May 26, 2023
·
2 min read
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
1 of 25,740
Next
